Tß4 Triggers Adult Stem Cells to Form new Blood Vessels and Repair Heart Tissue
Complete the form below to unlock access to ALL audio articles.
RegeneRx Biopharmaceuticals, Inc. announced that U.K. scientist, Paul R. Riley, Ph.D., Associate Professor at the Institute of Child Health in the United Kingdom and an expert in heart development and congenital heart disease, presented data that revealed the mechanism by which Tß4 may act to induce cardiac stem cells to differentiate and become cardiac blood vessels, thus, repairing the heart after a myocardial infarction (heart attack).
Professor Riley summarized his presentation by stating that Tß4 promotes vessel formation and collateral [blood vessel] growth not only during development but also from adult stem cells surrounding the heart and suggested that it has considerable therapeutic potential in man. His talk was entitled, “Thymosin ß4 Promotes Neovascularisation via Adult Epicardium: Translating Its Potential as a Novel Angiogenic Therapy.”
Professor Riley, who has conducted and published key research relating to RegeneRx’s Tß4 drug candidate, gave his presentation at the National Heart, Lung, and Blood Institute (NHLBI) Symposium on Cardiovascular Regenerative Medicine held on October 1-2, 2007. RegeneRx was one of several companies sponsoring the two-day symposium that focused on adult stem cell therapies for cardiovascular disease. In January 2007, Professor Riley and his colleagues published a scientific paper in the journal, Nature, on Tß4’s cardiac wound healing capabilities.
